Case Report
Grave’s Disease with Severe Hepatic Dysfunction: A Diagnostic and Therapeutic Challenge
Table 2
Follow-up investigations of the patient.
| | At adm. | 1st wk | 2nd wk | 3rd wk | At disch. | 2nd month | 5th month | 6th month |
| TSH (mIU/L) | 0.056 | | 0.28 | — | | | 0.45 | 0.78 | FT4 (ng/dL) (0.89–1.7) | 3.45 | | | | 2.1 | 1.9 | 1.69 | 1.24 | T3 (nmol/L) | 4.56 | | | | 3.34 | 3.3 | 2.67 | 2.01 | S. bilirubin (Total) (mg/dL) | 15.8 | 10.5 | 8.4 | 5.5 | 4.5 |
4.14 | 3.5 | 3.12 | Conjugated (mg/dL) | 12.6 | 8.4 | 5.6 | 3.4 | 3.1 | 2.89 | 1.6 | 1.45 | Unconjugated (mg/dL) | 1.5 | 0.8 | 0.7 | 0.5 | 1.1 | 0.6 | 0.45 | 0.67 | AST (U/L) | 46 | 43 | 35 | 33 | 34 | 38 | 39 | 32 | ALT (U/L) | 43 | 44 | 37 | 32 | 36 | 40 | 36 | 34 | Serum alkaline phosphatase (U/L) | 364 | 252 | 198 | 168 | 155 | 133 | 101 | 98 | S. Na+ (mmol/L) | 134 | 145 | 142 | 138 | 142 | 140 | 139 | 138 | S. K+ (mmol/L) | 2.7 | 3.8 | 4.1 | 4.3 | 4.0 | 3.9 | 4.1 | 3.9 |
|
|